Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial

Circulation

Volumn 94, Issue 11, 1996, Pages 2793-2799

  Packer, Milton ^a   Colucci, Wilson S ^b   Sackner Bernstein, Jonathan D ^a   Liang, Chang Seng ^c   Goldscher, David A ^d   Freeman, Israel ^e   Kukin, Marrick L ^f   Kinhal, Vithal ^g   Udelson, James E ^h   Klapholz, Marc ^a   Gottlieb, Stephen S ⁱ   Pearle, David ^j   Cody, Robert J ^k   Gregory, John J ^l   Kantrowitz, Nikki E ^f   LeJemtel, Thierry H ^m   Young, Sarah T ⁿ   Lukas, Mary Ann ⁿ   Shusterman, Neil H ⁿ  

^a Columbia University ^*  (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d GOOD SAMARITAN HOSPITAL   (United States)

^e NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^l OVERLOOK HOSPITAL   (United States)

^m ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁿ GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

blockers, beta adrenergic; carvedilol; heart failure

Indexed keywords

CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DYSPNEA; FATIGUE; FEMALE; HEART FAILURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VERTIGO;

EID: 10544251442     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2793     Document Type: Article

References (50)

1. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
2. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349-1355.
4. Dougherty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23:814-821.
5. Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J, Anderson ST, Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984;3:203-209.
6. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981;2:490-493.
7. Lipicky RJ, Packer M. Role of surrogate endpoints in the evaluation of drugs for heart failure. J Am Coll Cardiol. 1993;22:179A-184A.
8. Sable DL, Brammell HL, Sheehan MW, Nies AS, Gerber J, Horwitz LD. Attenuation of exercise conditioning by beta-adrenergic blockade. Circulation. 1982;65:679-684.
9. Marsh RC, Hiatt WR, Brammell HL, Horwitz LD. Attenuation of exercise conditioning by low dose beta adrenergic receptor blockade. J Am Coll Cardiol. 1983;2:551-556.
10. Goldsmith R, Krum H, Sackner-Bernstein J, Schwartz B, Neuberg GW, Penn J, Kukin ML, Packer M. Do changes in exercise tolerance reflect the clinical response to therapy in patients with heart failure? Implications for the design of clinical trials. Circulation. 1992;86(suppl I):I-513. Abstract.
11. Ruffolo RR, Gelai M, Heible JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(suppl 2): S82-S88.
12. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, Gin JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
13. Olsen SL, Gilbert EM, Renlund DC, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
14. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
15. Krum H, Sackner-Bernstein JD, Goldsmith R, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HL, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation. 1995;92:1499-1506.
16. Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure, pt 2: content, reliability and validity of a new measure, the Minnesota Living With Heart Failure Questionnaire. Heart Failure. 1987;3:198-209.
17. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The six-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
18. Sparrow J, Parameshar J, Poole-Wilson PA. Assessment of functional capacity in Chronic heart failure: time-limited exercise on a self-powered treadmill. Br Heart J. 1994;71:391-394.
19. Hart DJ, Katz SD, Lee SH, Ahern D, DeLong G, Whelan J, Packer M, Goldsmith RG. Characterization of the 9-minute self-powered treadmill walk, a new submaximal exercise test in patients with heart failure. J Am Coll Cardiol. 1994;23:384A. Abstract.
20. Packer M, Gheorghiade M, Young JB, Smith LK, Costantini PJ, Adams KF, Cody RJ, Gourley LA, Jolly MK, for the RADIANCE Study. Withdrawal of digoxin in patients with chronic heart failure treated with converting-enzyme inhibitors. N Engl J Med. 1993;329:1-7.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
22. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
23. Yushak M, Medina N, Krum H, Sackner-Bernstein J, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Packer M. Utility of direct symptom assessment in measuring the efficacy of therapy in chronic heart failure: evaluation in a controlled trial of beta-blockade. J Am Coll Cardiol. 1994;23:383A. Abstract.
24. Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol. 1987;9:433-438.
25. Richardson A, Bayliss J, Scriven A, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709-711.
26. Gundersen T, Swedberg K, Amtorp O, Remes J, Nilsson B. Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Eur Heart J. 1994;15:1659-1665.
27. McGrath BP, Arnoida L, Matthews PG, Jackson B, Jennings G, Kiat H, Johnston CI. Controlled trial of enalapril in congestive cardiac failure. Br Heart J. 1985;54:405-414.
28. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1962.
29. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677-683.
30. Parker JO, for the Ibopamine Study Group. The effects of oral ibopamine in patients with mild heart failure: a double-blind placebo controlled comparison to furosemide. Int J Cardiol. 1993;40:221-227.
31. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose response of chronic β-blocker treatment in heart failure from either idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
32. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, for the MOCHA Investigators. Multicenter oral carvedilol heart failure assessment (MOCHA): a six-month dose-response evaluation in class II-IV patients. Circulation. 1995;92(suppl I):I-142. Abstract.
33. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
34. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilalor-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
35. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
36. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
37. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol. in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546.
38. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.
39. Gilbert EM, Olsen SL, Mealey P, Volkman K, Larabee P, Bristow MR. Is β-receptor up-regulation necessary for improved left ventricular function in dilated cardiomyopathy? Circulation. 1991;84(suppl II):II-469. Abstract.
40. Packer M. The placebo effect in heart failure. Am Heart J. 1990;120:1579-1582.
41. Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolites of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J. 1981;102:210-221.
42. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects of the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
43. Wilmore JH, Ewy GA, Freund BJ, Hartzell AA, Jilka SM, Joyner MJ, Todd CA, Kinzer SM, Pepin EB. Cardiorespiratory alterations consequent to endurance exercise training during chronic beta-adrenergic blockade with atenolol and propranolol. Am J Cardiol. 1985;55:142D-148D.
44. 1 vs nonselective β-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation. 1995;92(suppl I):I-395. Abstract.
45. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:23C-29C.
46. Bristow MR, Olsen S, Gilbert EM, Larrabee PA, Volkman AK, Mealey PC, Ferguson D, While M, Renlund DG, O'Connell JB. β-Blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. J Am Coll Cardiol. 1992;19:146A. Abstract.
47. 1-selective and nonselective beta blockade on blood pressure relative to physical performance in men with systemic hypertension. Am J Cardiol 1985;55:79D-84D.
48. 2-adrenoceptor blockade on serum potassium and exercise performance in normal men. Br J Clin Pharmacol. 1991;32:201-207.
49. Dhalla AK, Singh N, Singal PK. Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation. 1994;90(suppl I):I-491. Abstract.
50. Bril A, Slivjak M, DiMartino MJ, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF III. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc Res. 1992;26:518-525.